SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: August 29, 1997
INTERNEURON PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
DELAWARE
- --------------------------------------------------------------------------------
(State of other jurisdiction of incorporation)
0-18728 043047911
------- ---------
(Commission File Number) (IRS Employer Identification No.)
One Ledgemont Center, 99 Hayden Avenue, Lexington, Massachusetts
- --------------------------------------------------------------------------------
(Address of principal executive offices)
02173
-----
(Zip Code)
Registrant's telephone no. including area code: (617) 861-8444
ITEM 5. OTHER EVENTS
On August 29, 1997, Interneuron Pharmaceuticals, Inc. (the "Company"),
was served with a complaint in Alabama state court naming 10 pharmaceutical
companies, including the Company, four weight-loss centers and one individual
physician in what purports to be a nationwide class action on behalf of all
persons who have suffered injury or who may suffer injury in the future due to
use of one or more weight loss drugs, including fenfluramine, phentermine, and
ReduxTM (dexfenfluramine). The suit alleges, among other things, that the
various drugs were negligently tested and marketed and that the companies failed
to adequately warn the medical community and patients of the risks associated
with use of the weight loss drugs, singly and in combination, and failed to
disclose pertinent information to the U.S. Food and Drug Administration. In
addition, the complaint alleges causes of action based on strict liability,
breach of warranty, negligent misrepresentation and fraud, and seeks an
unspecified aggregate amount of actual and punitive damages, as well as
injunctive relief. The Company intends to vigorously defend the action.
Except for the descriptions of historical facts contained herein, this
report contains forward-looking statements that involve risks and uncertainties
as detailed from time to time in the Company's filings under the Securities Act
of 1933 and the Securities Exchange Act of 1934, including in particular, risks
relating to the commercialization of Redux, such as marketing, safety and
regulatory, patent, product liability, litigation, supply, contractual
obligations, uncertainties relating to clinical trials and other risks.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERNEURON PHARMACEUTICALS INC.
By: /s/ Glenn L. Cooper
----------------------------------
Glenn L. Cooper, M.D.
President and Chief Executive Officer
Dated: September 4, 1997
